Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma
Open Access
- 2 February 2021
- Vol. 10 (2), 301
- https://doi.org/10.3390/cells10020301
Abstract
Neuroblastoma (NB) is the most common extracranial pediatric solid tumor. Children suffering from high-risk and/or metastatic NB often show no response to therapy, and new therapeutic approaches are urgently needed. Malignant tumor development has been shown to be driven by the dysregulation of eukaryotic initiation factors (eIFs) at the translation initiation. Especially the activity of the heterotrimeric eIF4F complex is often altered in malignant cells, since it is the direct connection to key oncogenic signaling pathways such as the PI3K/AKT/mTOR-pathway. A large body of literature exists that demonstrates targeting the translational machinery as a promising anti-neoplastic approach. The objective of this study was to determine whether eIF4F complex members are aberrantly expressed in NB and whether targeting parts of the complex may be a therapeutic strategy against NB. We show that eIF4AI is overexpressed in NB patient tissue using immunohistochemistry, immunoblotting, and RT-qPCR. NB cell lines exhibit decreased viability, increased apoptosis rates as well as changes in cell cycle distribution when treated with the synthetic rocaglate CR-1-31-B, which clamps eIF4A and eIF4F onto mRNA, resulting in a translational block. Additionally, this study reveals that CR-1-31-B is effective against NB cell lines at low nanomolar doses (≤20 nM), which have been shown to not affect non-malignant cells in previous studies. Thus, our study provides information of the expression status on eIF4AI in NB and offers initial promising insight into targeting translation initiation as an anti-tumorigenic approach for NB.Keywords
Funding Information
- Österreichische Forschungsförderungsgesellschaft (COMET CBmed)
- Styrian Children’s Cancer Foundation (1)
This publication has 39 references indexed in Scilit:
- Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration ApprovalClinical Lymphoma Myeloma and Leukemia, 2013
- Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinomaWorld Journal of Gastroenterology, 2012
- Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological StudiesJournal of Medicinal Chemistry, 2011
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, SilvestrolPLOS ONE, 2009
- Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26‐27 in squamous cell carcinoma of the lungInternational Journal of Cancer, 2007
- Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives from Aglaia silvestrisThe Journal of Organic Chemistry, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' capNature, 1990
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984